Wall Street brokerages expect DURECT Corporation (NASDAQ:DRRX) to post earnings of ($0.05) per share for the current quarter, Zacks reports. Three analysts have issued estimates for DURECT Corporation’s earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.06). DURECT Corporation reported earnings per share of ($0.06) in the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The business is scheduled to announce its next earnings results on Monday, October 30th.

On average, analysts expect that DURECT Corporation will report full-year earnings of ($0.20) per share for the current fiscal year, with EPS estimates ranging from ($0.24) to ($0.15). For the next financial year, analysts forecast that the company will post earnings of ($0.12) per share, with EPS estimates ranging from ($0.13) to ($0.11). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for DURECT Corporation.

DURECT Corporation (NASDAQ:DRRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02). DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. The business had revenue of $4.32 million for the quarter, compared to the consensus estimate of $5.17 million.

Several brokerages recently weighed in on DRRX. ValuEngine raised shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Stifel Nicolaus raised shares of DURECT Corporation from a “hold” rating to a “buy” rating and boosted their target price for the company from $1.25 to $3.00 in a research note on Wednesday, July 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of DURECT Corporation in a research note on Sunday, June 25th.

Shares of DURECT Corporation (DRRX) traded up 1.49% during trading on Tuesday, hitting $2.04. 379,083 shares of the company’s stock were exchanged. DURECT Corporation has a one year low of $0.74 and a one year high of $2.17. The firm has a 50-day moving average price of $1.71 and a 200-day moving average price of $1.42. The stock’s market cap is $299.88 million.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/10/zacks-brokerages-expect-durect-corporation-drrx-will-post-earnings-of-0-05-per-share.html.

A number of hedge funds have recently made changes to their positions in DRRX. Ingalls & Snyder LLC raised its stake in DURECT Corporation by 213.1% in the 2nd quarter. Ingalls & Snyder LLC now owns 6,419,482 shares of the specialty pharmaceutical company’s stock valued at $10,014,000 after purchasing an additional 4,369,400 shares during the last quarter. Asymmetry Capital Management L.P. acquired a new position in DURECT Corporation in the 2nd quarter valued at about $1,636,000. Stonepine Capital Management LLC raised its stake in DURECT Corporation by 28.6% in the 1st quarter. Stonepine Capital Management LLC now owns 2,801,376 shares of the specialty pharmaceutical company’s stock valued at $2,941,000 after purchasing an additional 623,585 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in DURECT Corporation by 48.4% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 1,200,000 shares of the specialty pharmaceutical company’s stock valued at $1,872,000 after purchasing an additional 391,500 shares during the last quarter. Finally, Mangrove Partners acquired a new position in DURECT Corporation in the 2nd quarter valued at about $530,000. 45.82% of the stock is owned by hedge funds and other institutional investors.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Get a free copy of the Zacks research report on DURECT Corporation (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.